SEC filings reveal that last week atai Life Sciences disposed of around 2.7 million Compass Pathways shares for gross proceeds of just over $16 million. That represents around a third of atai’s stake in Compass. The sale comes as Compass is expected to share a first cut of data from its Phase 3 program of its psilocybin candidate (COMP360) for treatment-resistant depression…
